IP Verse

Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma

Patent No. EP3463457 (titled "Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma") was filed by Bristol Myers Squibb on Jun 1, 2017. The application was issued on Jun 28, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
PAJAROMar 27, 2024BIRD & BIRD
STRAWMANMar 22, 2024HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3463457

BRISTOL MYERS SQUIBB
Application Number
EP17730627A
Filing Date
Jun 1, 2017
Status
Granted And Under Opposition
May 26, 2023
Publication Date
Jun 28, 2023
External Links
Slate, Register , Google Patents